Jeff Brum — Pharmaceutical Analysis, CMC

A recognized leader and innovator in product development, Dr. Brum has extensive experience in delivering CMC analytical control strategies underpinning successful process development from preclinical to commercialization.  As Scientific Director at GSK he formed and led the innovative Global Structural Properties Group combining state of the art characterization and computational tools providing fundamental product understanding.  Previously he led a variety of diverse groups and departments in both solid-state and chemical characterization.  Dr. Brum has successfully led CMC product development matrix teams and has managed lifecycle support for a marketed medicine.  He was a key contributor to six NDA/MMA filings, technology transfers, and subsequent product commercialization as well as numerous earlier phase dossiers.

A long-time member of the organizing committee of the International Workshop for Physical Characterization of Pharmaceutical Solids, Jeff has over 75 publications and presentations and was recognized as a GSK Senior Fellow for scientific excellence supporting product development and driving innovation.  He brings deep technical expertise in chemical, physical and structural analysis of API and formulated product including OSD, SDD, and nanoparticle-based systems.  Also, Dr. Brum is recognized for a substantial knowledge of solid-state form relationships and stability, particle and surface characterization, and the impact of water in a range of pharmaceutical systems.

Expertise